Genetic Technologies Ltd (GENE) - Net Assets
Based on the latest financial reports, Genetic Technologies Ltd (GENE) has net assets worth $1.83 Million USD as of June 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.19 Million) and total liabilities ($4.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GENE cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.83 Million |
| % of Total Assets | 29.59% |
| Annual Growth Rate | -5.75% |
| 5-Year Change | -86.92% |
| 10-Year Change | -90.35% |
| Growth Volatility | 245.97 |
Genetic Technologies Ltd - Net Assets Trend (2000–2024)
This chart illustrates how Genetic Technologies Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Genetic Technologies Ltd's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Genetic Technologies Ltd (2000–2024)
The table below shows the annual net assets of Genetic Technologies Ltd from 2000 to 2024. For live valuation and market cap data, see Genetic Technologies Ltd (GENE) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | $1.83 Million | -83.60% |
| 2023-06-30 | $11.16 Million | -32.06% |
| 2022-06-30 | $16.43 Million | -23.69% |
| 2021-06-30 | $21.53 Million | +53.89% |
| 2020-06-30 | $13.99 Million | +690.00% |
| 2019-06-30 | $1.77 Million | -62.41% |
| 2018-06-30 | $4.71 Million | -55.46% |
| 2017-06-30 | $10.58 Million | -10.97% |
| 2016-06-30 | $11.88 Million | -37.32% |
| 2015-06-30 | $18.96 Million | +937.43% |
| 2014-06-30 | $1.83 Million | -68.26% |
| 2013-06-30 | $5.76 Million | -60.02% |
| 2012-06-30 | $14.40 Million | +111.37% |
| 2011-06-30 | $6.81 Million | +19.17% |
| 2010-06-30 | $5.72 Million | -67.30% |
| 2009-06-30 | $17.49 Million | -16.05% |
| 2008-06-30 | $20.83 Million | +23.24% |
| 2007-06-30 | $16.90 Million | -7.47% |
| 2006-06-30 | $18.27 Million | -19.73% |
| 2005-06-30 | $22.75 Million | +33.31% |
| 2004-06-30 | $17.07 Million | -37.42% |
| 2003-06-30 | $27.28 Million | -12.39% |
| 2002-06-30 | $31.14 Million | -18.21% |
| 2001-06-30 | $38.07 Million | +402.40% |
| 2000-06-30 | $7.58 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genetic Technologies Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15185925600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $163.82 Million | 8949.77% |
| Other Comprehensive Income | $4.39 Million | 239.76% |
| Total Equity | $1.83 Million | 100.00% |
Genetic Technologies Ltd Competitors by Market Cap
The table below lists competitors of Genetic Technologies Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LM Funding America Inc
NASDAQ:LMFA
|
$3.71 Million |
|
Frp Advisory Group Plc
LSE:FRP
|
$3.71 Million |
|
Avira Resources Ltd
AU:AVW
|
$3.71 Million |
|
Mega Sun City Holdings Bhd
KLSE:0081
|
$3.72 Million |
|
ATI Physical Therapy Inc
NYSE:ATIP
|
$3.71 Million |
|
Triboron International AB (publ)
ST:TRIBO-B
|
$3.70 Million |
|
Opawica Explorations Inc
V:OPW
|
$3.70 Million |
|
Imagine Lithium Inc
V:ILI
|
$3.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genetic Technologies Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 11,162,576 to 1,830,415, a change of -9,332,161 (-83.6%).
- Net loss of 12,017,219 reduced equity.
- New share issuances of 2,577,147 increased equity.
- Other comprehensive income decreased equity by 2,146,928.
- Other factors increased equity by 2,254,839.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.02 Million | -656.53% |
| Share Issuances | $2.58 Million | +140.8% |
| Other Comprehensive Income | $-2.15 Million | -117.29% |
| Other Changes | $2.25 Million | +123.19% |
| Total Change | $- | -83.60% |
Book Value vs Market Value Analysis
This analysis compares Genetic Technologies Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4795.63x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 23641.65x to 4795.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-06-30 | $0.08 | $1903.20 | x |
| 2001-06-30 | $4.81 | $1903.20 | x |
| 2002-06-30 | $3.36 | $1903.20 | x |
| 2003-06-30 | $2.92 | $1903.20 | x |
| 2004-06-30 | $1.71 | $1903.20 | x |
| 2005-06-30 | $2.01 | $1903.20 | x |
| 2006-06-30 | $1.40 | $1903.20 | x |
| 2007-06-30 | $1.29 | $1903.20 | x |
| 2008-06-30 | $1.60 | $1903.20 | x |
| 2009-06-30 | $1.30 | $1903.20 | x |
| 2010-06-30 | $0.41 | $1903.20 | x |
| 2011-06-30 | $0.46 | $1903.20 | x |
| 2012-06-30 | $0.87 | $1903.20 | x |
| 2013-06-30 | $0.67 | $1903.20 | x |
| 2014-06-30 | $0.22 | $1903.20 | x |
| 2015-06-30 | $53.02 | $1903.20 | x |
| 2016-06-30 | $20.78 | $1903.20 | x |
| 2017-06-30 | $14.96 | $1903.20 | x |
| 2018-06-30 | $5.80 | $1903.20 | x |
| 2019-06-30 | $1.88 | $1903.20 | x |
| 2020-06-30 | $10.10 | $1903.20 | x |
| 2021-06-30 | $7.56 | $1903.20 | x |
| 2022-06-30 | $5.35 | $1903.20 | x |
| 2023-06-30 | $3.30 | $1903.20 | x |
| 2024-06-30 | $0.40 | $1903.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genetic Technologies Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -656.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -156.78%
- • Asset Turnover: 1.24x
- • Equity Multiplier: 3.38x
- Recent ROE (-656.53%) is below the historical average (-111.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | -32.20% | -60.71% | 0.45x | 1.17x | $-3.20 Million |
| 2001 | -8.91% | -60.19% | 0.14x | 1.04x | $-7.20 Million |
| 2002 | -28.34% | -67.33% | 0.40x | 1.06x | $-11.94 Million |
| 2003 | -15.86% | -46.69% | 0.31x | 1.11x | $-7.05 Million |
| 2004 | -40.64% | -182.11% | 0.17x | 1.32x | $-8.58 Million |
| 2005 | -33.34% | -79.54% | 0.32x | 1.30x | $-9.79 Million |
| 2006 | -29.95% | -54.74% | 0.44x | 1.24x | $-7.23 Million |
| 2007 | -9.94% | -12.11% | 0.66x | 1.25x | $-3.34 Million |
| 2008 | -26.38% | -34.68% | 0.65x | 1.17x | $-7.53 Million |
| 2009 | -56.18% | -145.69% | 0.30x | 1.29x | $-11.45 Million |
| 2010 | -168.87% | -95.77% | 1.18x | 1.50x | $-9.90 Million |
| 2011 | 13.76% | 4.98% | 2.05x | 1.35x | $248.80K |
| 2012 | -37.11% | -46.66% | 0.69x | 1.15x | $-6.71 Million |
| 2013 | -165.84% | -276.84% | 0.41x | 1.48x | $-9.91 Million |
| 2014 | -554.04% | -221.84% | 0.68x | 3.68x | $-10.31 Million |
| 2015 | -46.47% | -437.90% | 0.10x | 1.09x | $-10.71 Million |
| 2016 | -71.18% | -1025.84% | 0.06x | 1.12x | $-9.65 Million |
| 2017 | -79.44% | -1620.78% | 0.04x | 1.14x | $-9.46 Million |
| 2018 | -115.96% | -2887.06% | 0.03x | 1.31x | $-5.94 Million |
| 2019 | -385.79% | -26855.39% | 0.01x | 1.84x | $-7.01 Million |
| 2020 | -45.05% | -63909.94% | 0.00x | 1.12x | $-7.70 Million |
| 2021 | -33.47% | -5979.01% | 0.01x | 1.07x | $-9.36 Million |
| 2022 | -43.40% | -104.95% | 0.33x | 1.27x | $-8.77 Million |
| 2023 | -105.27% | -113.56% | 0.70x | 1.33x | $-12.87 Million |
| 2024 | -656.53% | -156.78% | 1.24x | 3.38x | $-12.20 Million |
Industry Comparison
This section compares Genetic Technologies Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $694,923,903
- Average return on equity (ROE) among peers: -98.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genetic Technologies Ltd (GENE) | $1.83 Million | -32.20% | 2.38x | $3.71 Million |
| Agilent Technologies Inc (A) | $5.90 Billion | 21.85% | 1.01x | $32.42 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.49 Million | -115.35% | 0.92x | $7.19 Million |
| Applied DNA Sciences Inc (APDN) | $5.71 Million | -223.57% | 0.99x | $3.99 Million |
| Biodesix Inc (BDSX) | $-228.54 Million | 0.00% | 0.00x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $9.85 Million |
| Biocept Inc. (BIOCQ) | $11.20 Million | -224.43% | 0.58x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $30.47 Million | -271.32% | 5.29x | $3.21 Billion |
| Burning Rock Biotech Ltd (BNR) | $768.41 Million | -85.07% | 0.35x | $154.44 Million |
| CareDx Inc (CDNA) | $465.88 Million | -6.58% | 0.22x | $1.00 Billion |
| Check Cap Ltd (CHEK) | $10.41 Million | -84.81% | 0.18x | $9.42 Million |
About Genetic Technologies Ltd
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinicall… Read more